Drug-refractory irritability and related factors in autistic children

Basit Öğe Kaydı
dc.authoridAlnak, Alper/0000-0002-3515-8217
dc.authoridAykutlu, Hasan Cem/0000-0002-4809-4857
dc.authorwosidAlnak, Alper/ABS-2152-2022
dc.contributor.authorAykutlu, Hasan C.
dc.contributor.authorBozatli, Leyla
dc.contributor.authorGorker, Isik
dc.contributor.authorOkyar, Esra
dc.contributor.authorUzun-Cicek, Ayla
dc.contributor.authorUcuz, Ilknur
dc.contributor.authorDogru, Hicran
dc.date.accessioned2024-06-12T10:52:55Z
dc.date.available2024-06-12T10:52:55Z
dc.date.issued2024
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectivesAutistic children frequently exhibit irritability, which can manifest as aggression, self-injurious behaviour, and severe tantrums, leading to significant impairments. Two atypical antipsychotics have been licensed by the Food and Drug Administration for the treatment of irritability in autistic children, although a significant percentage of these children do not respond to this treatment. This study aimed to determine the frequency of drug refractory irritability (DRI) and identify the risk factors in a large clinical sample of autistic children.MethodsThe medical records of 1279 children aged 2-18 years diagnosed with autism and undergoing clinical follow-up were retrospectively analysed. Socioeconomic and clinical characteristics, co-occurring psychiatric disorders and physical conditions were recorded.Results55% of the sample used antipsychotics to treat irritability, and 8.2% met the DRI criteria. Older age, severe support requirement for autism, language impairment, anxiety disorders, sleep difficulties, gastrointestinal system, and dental problems were found to significantly increase the risk of DRI.ConclusionOur findings indicate that a significant proportion of the clinical sample of autistic children had DRI. The physical, psychiatric, and environmental risk factors identified in our study also highlight heterogeneity in the etiology of DRI. Further research on DRI is needed to develop treatment and prevention strategies.en_US
dc.identifier.doi10.1080/20473869.2024.2327790
dc.identifier.issn2047-3869
dc.identifier.issn2047-3877
dc.identifier.scopus2-s2.0-85188503133en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1080/20473869.2024.2327790
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18883
dc.identifier.wosWOS:001187500200001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofInternational Journal Of Developmental Disabilitiesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAutism Spectrum Disordersen_US
dc.subjectIrritabilityen_US
dc.subjectChallenging Behaviouren_US
dc.subjectDrug Refractoryen_US
dc.subjectChildrenen_US
dc.subjectSelf-Injurious Behaviorsen_US
dc.subjectSpectrum Disorderen_US
dc.subjectChallenging Behaviorsen_US
dc.subjectGastrointestinal Symptomsen_US
dc.subjectAdolescentsen_US
dc.subjectAggressionen_US
dc.subjectAripiprazoleen_US
dc.subjectIndividualsen_US
dc.subjectRisperidoneen_US
dc.subjectSeverityen_US
dc.titleDrug-refractory irritability and related factors in autistic childrenen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu